DNA-encoded chemistry discovery platform with AI-driven screening
X-Chem runs a drug-discovery operation built on DNA-encoded chemical libraries paired with computational chemistry and machine learning. The tech stack reveals a data-heavy organization — Python, R, RDKit for cheminformatics; PostgreSQL, MongoDB, Oracle for persistence; AWS for compute; Salesforce + NetSuite for operations — combined with a pronounced project focus on data governance, pipeline standardization, and bridging wet-lab science with computational tools. The hiring profile (research-dominant, steady growth, global footprint) and pain-point clustering around data integration and scientist-technologist alignment suggest X-Chem is scaling operational maturity to keep pace with discovery throughput.
X-Chem is a small-molecule drug-discovery partner for pharmaceutical and biotech companies. Founded in 2010 and headquartered in Waltham, MA, the company operates at 201–500 employees. The business model centers on de novo molecule generation using DNA-encoded library screening, hit validation, and AI-guided optimization. Clients access X-Chem's capabilities through integrated project management (screen-to-hit through candidate identification phases), software licensing (ArtemisAI platform), or hybrid engagements. The organization has delivered ~100 licensed programs and 4 clinical candidates since 2021, with demonstrated success across ~30 target classes.
X-Chem uses Python, R, and RDKit for computational chemistry; PostgreSQL, MongoDB, and Oracle for data storage; AWS (EKS, Lambda) for cloud infrastructure; Salesforce and NetSuite for enterprise operations; and Power BI and Tableau for analytics.
Active projects center on computational chemistry support, data governance standardization, pipeline integration across wet-lab and computational workflows, enterprise system data flows, and self-service analytics dashboards — reflecting an organizational shift toward operational scale.
Other companies in the same industry, closest in size